These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 9605156)

  • 1. Differential requirement for CD4 help in the development of an antigen-specific CD8+ T cell response depending on the route of immunization.
    Bour H; Horvath C; Lurquin C; Cerottini JC; MacDonald HR
    J Immunol; 1998 Jun; 160(11):5522-9. PubMed ID: 9605156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-derived interleukin-4 reduces tumor clearance and deviates the cytokine and granzyme profile of tumor-induced CD8+ T cells.
    Olver S; Groves P; Buttigieg K; Morris ES; Janas ML; Kelso A; Kienzle N
    Cancer Res; 2006 Jan; 66(1):571-80. PubMed ID: 16397274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flow-microfluorometric monitoring of oligoclonal CD8+ T cell responses to an immunodominant Moloney leukemia virus-encoded epitope in vivo.
    Brawand P; Biasi G; Horvath C; Cerottini JC; MacDonald HR
    J Immunol; 1998 Feb; 160(4):1659-65. PubMed ID: 9469422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dramatic influence of V beta gene polymorphism on an antigen-specific CD8+ T cell response in vivo.
    Bour H; Michielin O; Bousso P; Cerottini JC; MacDonald HR
    J Immunol; 1999 Apr; 162(8):4647-56. PubMed ID: 10202004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mapping of HLA epitopes recognized by H-2-restricted cytotoxic T lymphocytes specific for HLA using recombinant genes and synthetic peptides.
    Pala P; Corradin G; Strachan T; Sodoyer R; Jordan BR; Cerottini JC; Maryanski JL
    J Immunol; 1988 Feb; 140(3):871-7. PubMed ID: 2448379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the HLA-Cw3-specific cytotoxic T lymphocyte response of HLA-B7 X human beta 2m double transgenic mice.
    Barra C; Pérarnau B; Gerlinger P; Lemeur M; Gillet A; Gibier P; Lemonnier FA
    J Immunol; 1989 Nov; 143(10):3117-24. PubMed ID: 2478616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma.
    Li Y; McGowan P; Hellström I; Hellström KE; Chen L
    J Immunol; 1994 Jul; 153(1):421-8. PubMed ID: 7515929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Requirement for CD4 T cell help in generating functional CD8 T cell memory.
    Shedlock DJ; Shen H
    Science; 2003 Apr; 300(5617):337-9. PubMed ID: 12690201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Augmented induction of CD8+ cytotoxic T-cell response and antitumour resistance by T helper type 1-inducing peptide.
    Kikuchi T; Uehara S; Ariga H; Tokunaga T; Kariyone A; Tamura T; Takatsu K
    Immunology; 2006 Jan; 117(1):47-58. PubMed ID: 16423040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Host B7-1 and B7-2 costimulatory molecules contribute to the eradication of B7-1-transfected P815 tumor cells via a CD8+ T cell-dependent mechanism.
    La Motte RN; Sharpe AH; Bluestone JA; Mokyr MB
    J Immunol; 1999 Apr; 162(8):4817-23. PubMed ID: 10202025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rejection of an IA+ variant line of FBL-3 leukemia by cytotoxic T lymphocytes with CD4+ and CD4-CD8- T cell receptor-alpha beta phenotypes generated in CD8-depleted C57BL/6 mice.
    Yoshimura A; Shiku H; Nakayama E
    J Immunol; 1993 Jun; 150(11):4900-10. PubMed ID: 8496592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Qualitative differences between naive and memory T cells make a major contribution to the more rapid and efficient memory CD8+ T cell response.
    Kedl RM; Mescher MF
    J Immunol; 1998 Jul; 161(2):674-83. PubMed ID: 9670942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The immunologic function of 1B2+ double negative (CD4-CD8-) T cells in the 2C transgenic mouse.
    Margenthaler JA; Flye MW
    J Surg Res; 2005 Jun; 126(2):160-6. PubMed ID: 15919414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simian virus 40 large-T-antigen-specific rejection of mKSA tumor cells in BALB/c mice is critically dependent on both strictly tumor-associated, tumor-specific CD8(+) cytotoxic T lymphocytes and CD4(+) T helper cells.
    Utermöhlen O; Schulze-Garg C; Warnecke G; Gugel R; Löhler J; Deppert W
    J Virol; 2001 Nov; 75(22):10593-602. PubMed ID: 11602701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and antigen specificity of CD8+ cytotoxic T lymphocytes in beta 2-microglobulin-negative, MHC class I-deficient mice in response to immunization with tumor cells.
    Apasov SG; Sitkovsky MV
    J Immunol; 1994 Mar; 152(5):2087-97. PubMed ID: 8133027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a ras oncogene peptide that contains both CD4(+) and CD8(+) T cell epitopes in a nested configuration and elicits both T cell subset responses by peptide or DNA immunization.
    Bristol JA; Orsini C; Lindinger P; Thalhamer J; Abrams SI
    Cell Immunol; 2000 Nov; 205(2):73-83. PubMed ID: 11104579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistence, immune specificity, and functional ability of murine mutant ras epitope-specific CD4(+) and CD8(+) T lymphocytes following in vivo adoptive transfer.
    Bristol JA; Schlom J; Abrams SI
    Cell Immunol; 1999 May; 194(1):78-89. PubMed ID: 10357883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD8+ cell activation to a major mastocytoma rejection antigen, P815AB: requirement for tum- or helper peptides in priming for skin test reactivity to a P815AB-related peptide.
    Grohmann U; Bianchi R; Fioretti MC; Fallarino F; Binaglia L; Uyttenhove C; Van Pel A; Boon T; Puccetti P
    Eur J Immunol; 1995 Oct; 25(10):2797-802. PubMed ID: 7589074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The brain parenchyma is permissive for full antitumor CTL effector function, even in the absence of CD4 T cells.
    Walker PR; Calzascia T; Schnuriger V; Scamuffa N; Saas P; de Tribolet N; Dietrich PY
    J Immunol; 2000 Sep; 165(6):3128-35. PubMed ID: 10975826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies on the minimum requirements for in vitro "cure" of tumor cells by cytotoxic T lymphocytes.
    Miki S; Ksander B; Streilein JW
    Reg Immunol; 1992; 4(6):352-62. PubMed ID: 1297406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.